Anixa Biosciences (ANIX) Projected to Post Quarterly Earnings on Tuesday

Anixa Biosciences (NASDAQ:ANIX) will likely be posting its quarterly earnings results before the market opens on Tuesday, January 21st. Analysts expect Anixa Biosciences to post earnings of ($0.11) per share for the quarter.

Anixa Biosciences (NASDAQ:ANIX) last issued its earnings results on Friday, January 10th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.02. On average, analysts expect Anixa Biosciences to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Anixa Biosciences Price Performance

Shares of ANIX traded up $0.15 during mid-day trading on Wednesday, reaching $2.28. The company had a trading volume of 304,351 shares, compared to its average volume of 102,889. Anixa Biosciences has a twelve month low of $2.07 and a twelve month high of $5.13. The company’s 50-day moving average is $2.86 and its 200-day moving average is $3.03. The company has a market capitalization of $73.37 million, a P/E ratio of -5.85 and a beta of 0.82.

Insider Activity at Anixa Biosciences

In other Anixa Biosciences news, CEO Amit Kumar purchased 43,000 shares of the company’s stock in a transaction that occurred on Wednesday, January 15th. The stock was purchased at an average cost of $2.23 per share, with a total value of $95,890.00. Following the acquisition, the chief executive officer now directly owns 559,925 shares of the company’s stock, valued at approximately $1,248,632.75. This trade represents a 8.32 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. Insiders own 22.60% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on ANIX shares. D. Boral Capital reissued a “buy” rating and issued a $10.00 target price on shares of Anixa Biosciences in a report on Tuesday. HC Wainwright reissued a “buy” rating and issued a $7.00 target price on shares of Anixa Biosciences in a report on Tuesday, November 19th.

About Anixa Biosciences

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.